Bayer AG announced on Wednesday that its sales in the second quarter of the fiscal year 2025 observed an annual decline of 3.6% to land at €10.7 billion. The pharmaceutical company's net loss went from €34 million seen in the same trimester the year before to €199 million. Meanwhile, its losses per share worsened from €0.03 a year ago to €0.20.
In the first half of the year, Bayer's sales decreased by 1.7% compared to the same period in 2024 to €24.5 billion. Its net income dropped by 44% to €1.1 billion, while its earnings per share (EPS) went down by 44% to €1.12.
"We affirm our objective to significantly contain the litigation risk by the end of 2026," Chief Executive Officer (CEO) Bill Anderson said. "Beyond the operational success of our Pharma business, we continue to see newsflow on our pipeline and launch assets."
